Respicardia
Developing implantable therapies designed to improve respiratory rhythm management and cardiovascular health.
Launch date
Employees
Market cap
-
Enterprise valuation
€213—319m (Dealroom.co estimates Dec 2017.)
Minnetonka Minnesota (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
$5.5m | Series A | ||
$21.0m | Series B | ||
$27.0m | Series C | ||
$10.0m | Series D | ||
N/A | $2.0m | Convertible | |
N/A | $20.0m | Late VC | |
$5.1m | Debt | ||
$58.5m | Late VC | ||
N/A | Acquisition | ||
Total Funding | €131m |
Recent News about Respicardia
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.